Subinoy Das, MD, FACS, FARS, Chief Executive Officer and Interim Medical Director for the U.S. Institute for Advanced Sinus Care and Research recently posted an update for their ongoing efforts on the treatment of Empty Nose Syndrome. In the update, Dr. Das discussed the variety of services offered for patients with ENS and other nasal/sinus related disorders. As of September 17th, 2017, 392 patients have been treated for ENS with PRP/Acell Injections; 52 adipose-derived autologous fat transfers have been performed; Alloderm implants are offered again. They are now soaked with PRP/Acell/Adipose-derived stromal vascular fraction.

On the subject of new therapies, Dr. Das stated that there are several advances in stem cell and regenerative therapy for the nose, but these are several years from becoming clinically available. He noted they will consider participating in clinical trials when the new therapies are being tested for FDA approval in the United States.